Johnson & Johnson has agreed to pay $181 million to resolve allegations of inappropriate marketing of the drug Risperdal. Thirty-six states and the District of Columbia will share in the settlement money.
The lawsuit alleges that Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson, marketed Risperdal for off-label uses, targeting patients with Alzheimer’s disease, dementia, depression, and anxiety. These uses aren’t FDA-approved and Janssen never established that the drug was safe and effective for them.
Along with the District of Columbia, the following states participated in the settlement: Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, Wisconsin, and Wyoming.
This agreement is separate from a continuing federal investigation that could lead to criminal charges against the company. Reports suggest a settlement of that investigation could reach $2 billion.
For more information, please see: